UKCA Marking for Patches: Post-Brexit Guide for Brands

Since Brexit, the regulatory landscape for medical devices in the UK has undergone significant changes. For patch brands, understanding UKCA marking is no longer optional—it’s a legal requirement to access the UK market. This comprehensive guide will walk you through everything you need to know about UKCA marking for patches, from deadlines to documentation, ensuring your products remain compliant and competitive.

Key Takeaways

• UKCA marking replaces CE marking for medical devices in Great Britain (England, Scotland, Wales) and became mandatory on 1 July 2023 for most devices.
• Patch brands must register with the MHRA before placing devices on the UK market, with fees starting at £100 for Class I devices.
• Northern Ireland follows different rules: CE marking or UKNI marking may be used, and UKCA marking alone is not accepted.
• Technical documentation must be updated to include UK-specific requirements, such as a UK Responsible Person and UKCA conformity assessment.
• Post-Brexit, the UK medical device market is valued at over £5 billion, with transdermal patches representing a growing segment due to aging populations and chronic diseases.
• Partnering with an experienced OEM like Kongdy Health can streamline compliance, as we hold ISO 13485, FDA, and GMP certifications and have extensive experience with UK regulatory submissions.

Transitioning to UKCA marking involves more than just a new logo; it requires a thorough review of your quality management system, technical files, and labeling. With deadlines already passed for most devices, it’s crucial to act swiftly. In this article, we’ll explore the key steps, common pitfalls, and strategic considerations for patch brands navigating the post-Brexit UK regulatory environment.

Understanding UKCA Marking and Its Impact on Patch Brands

UKCA (UK Conformity Assessed) marking is the new product marking for goods placed on the market in Great Britain (GB), which includes England, Scotland, and Wales. It replaces the CE marking for most medical devices, including transdermal patches. The UK government introduced UKCA marking to maintain regulatory autonomy after leaving the European Union. For patch brands, this means that any device currently bearing CE marking must transition to UKCA marking to continue selling in GB. The deadline for compliance was 1 July 2023 for most devices, although some flexibility was granted for certain low-risk devices until 2028. However, it’s essential to verify the specific timeline for your device classification.

The impact on patch brands is multifaceted. First, you must ensure your device meets UK-specific essential requirements, which are largely aligned with EU MDR but may have subtle differences. Second, you need to appoint a UK Responsible Person if your manufacturing site is outside the UK. Third, your technical documentation must be updated to reflect UKCA compliance, including a UK Declaration of Conformity. Finally, your labeling must include the UKCA mark and the name and address of the UK Responsible Person. These changes require careful planning and resource allocation.

According to the MHRA, as of 2023, there are over 80,000 medical devices registered in the UK, with transdermal patches constituting a significant portion of the drug-device combination products. The UK market for transdermal patches is estimated at £500 million annually, growing at a CAGR of 6% (Grand View Research, 2022). This growth underscores the importance of maintaining market access through timely UKCA compliance.

MHRA Registration: The First Step to UK Market Access

Before you can apply UKCA marking, you must register your device with the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA is the UK’s regulatory authority for medical devices, and registration is mandatory for all devices placed on the GB market. The registration process involves submitting details about your device, including its classification, intended use, and manufacturer information. For patches, which are often classified as Class IIa or IIb depending on their drug component, the registration fees vary. As of 2023, the fee for registering a Class IIa device is £1,000, while Class IIb is £2,000. These fees are payable to the MHRA and are separate from any conformity assessment costs.

It’s important to note that registration is not a one-time event. You must update your registration if there are significant changes to your device, such as modifications to its design, intended purpose, or manufacturing process. Additionally, if you are a manufacturer based outside the UK, you must appoint a UK Responsible Person who will handle the registration on your behalf. The UK Responsible Person must be established in the UK and is legally responsible for ensuring compliance with UK regulations. This role is similar to the EU Authorized Representative under the MDR.

The MHRA has been actively enforcing registration requirements. In 2022, the agency issued over 200 warning letters to companies for non-compliance, resulting in product recalls and fines. Therefore, patch brands must prioritize MHRA registration to avoid disruptions. Partnering with a contract manufacturer like Kongdy Health, which has extensive experience with MHRA submissions, can simplify this process. Our team stays updated on the latest MHRA guidance and can assist with all documentation.

Key Steps to Achieve UKCA Marking for Transdermal Patches

Achieving UKCA marking requires a systematic approach. Below is a detailed numbered list of steps to guide you through the process:

1. Determine Device Classification: Under UK MDR, transdermal patches are typically classified as Class IIa or IIb, depending on the drug’s mode of action and potential risks. This classification dictates the conformity assessment route. For example, a patch delivering a hormone like estrogen may be Class IIb, while a nicotine patch is Class IIa.
2. Appoint a UK Responsible Person: If your manufacturing site is outside the UK, you must appoint a UK Responsible Person. This entity will act as your legal representative, handle MHRA communications, and ensure compliance. The UK Responsible Person must be registered with the MHRA.
3. Prepare Technical Documentation: Compile a comprehensive technical file that includes device description, design and manufacturing information, risk analysis, clinical evaluation, and labeling. Ensure it meets UK MDR requirements, which are largely harmonized with EU MDR but may have national deviations.
4. Conduct Conformity Assessment: For Class IIa and IIb devices, you need a UK Approved Body to assess your quality management system and technical documentation. This is similar to the EU Notified Body process. As of 2023, there are only a few UK Approved Bodies, so early engagement is crucial to avoid delays.
5. Issue UK Declaration of Conformity: Once conformity is established, you must draft a UK Declaration of Conformity, which lists the applicable UK legislation and standards. This document must be signed by a responsible person within your organization.
6. Affix UKCA Mark: The UKCA mark must be affixed to the device or its packaging. It must be visible, legible, and indelible. For patches, the mark can be placed on the primary packaging or the patch itself if space permits.
7. Register with MHRA: Submit your device registration to the MHRA, paying the applicable fee. You must also update your registration annually.
8. Maintain Post-Market Surveillance: Establish a system for monitoring device performance, reporting adverse events, and conducting field safety corrective actions. This is an ongoing requirement under UK MDR.

Each step requires careful attention to detail. For instance, the technical documentation must include a gap analysis comparing EU MDR and UK MDR requirements. Many brands overlook this, leading to delays. Working with a seasoned OEM like Kongdy Health can help you navigate these complexities efficiently.

Common Pitfalls and How to Avoid Them

Transitioning to UKCA marking is fraught with potential pitfalls. One common mistake is assuming that CE marking compliance automatically translates to UKCA compliance. While the requirements are similar, there are differences in labeling, registration, and conformity assessment. For example, the UKCA mark must be accompanied by the UK Responsible Person’s details, which is not required for CE marking. Another pitfall is underestimating the time required for UK Approved Body review. With limited capacity, reviews can take several months, so early planning is essential.

Additionally, many brands fail to update their post-market surveillance systems to include UK-specific reporting. The MHRA requires that adverse events be reported within specific timelines, and non-compliance can lead to penalties. Furthermore, some brands neglect to update their quality management system documentation, such as SOPs and work instructions, to reflect UKCA requirements. This can result in audit findings and certification delays.

To avoid these pitfalls, consider the following bullet-point list of best practices:

• Conduct a thorough gap analysis between EU MDR and UK MDR requirements, focusing on labeling, registration, and conformity assessment.
• Engage a UK Approved Body early in the process to secure a slot and avoid last-minute rushes.
• Ensure your UK Responsible Person is knowledgeable and responsive, as they will be your primary contact with the MHRA.
• Update your technical documentation to include UK-specific standards, such as those published by BSI.
• Train your regulatory team on UK MDR nuances, including the differences in classification rules.
• Implement a robust post-market surveillance system that captures UK-specific data and reporting requirements.
• Consider dual marking (CE and UKCA) if you sell in both the EU and UK, but ensure the marks are correctly applied and not confusing.

By following these best practices, patch brands can streamline their UKCA transition and maintain uninterrupted market access.

Market Trends and Statistics: The UK Transdermal Patch Landscape

The UK transdermal patch market is poised for steady growth, driven by an aging population and the increasing prevalence of chronic diseases such as pain, cardiovascular conditions, and neurological disorders. According to a 2022 report by Grand View Research, the global transdermal patch market size was valued at USD 7.3 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.5% from 2022 to 2030. The UK market accounts for approximately 7% of the European market, with an estimated value of £500 million in 2022. This growth is fueled by the convenience of patches, improved patient adherence, and advancements in drug delivery technologies.

Another key trend is the shift towards personalized medicine, which is driving demand for customized patch formulations. Additionally, the COVID-19 pandemic accelerated the adoption of telemedicine and home-based care, further boosting the use of transdermal patches for remote patient monitoring. As a result, patch brands are investing in R&D to develop innovative products that cater to specific patient needs. However, regulatory hurdles such as UKCA marking can slow down market entry if not managed properly.

From a competitive standpoint, the UK market is characterized by the presence of both global players and local manufacturers. To succeed, brands must differentiate through quality, efficacy, and compliance. Partnering with a reliable OEM like Kongdy Health, which has been manufacturing transdermal patches since 1989 and serves over 120 countries, can provide a competitive edge. Our certifications, including ISO 13485, FDA, and GMP, ensure that your products meet the highest regulatory standards.

How Kongdy Health Can Support Your UKCA Compliance Journey

As an experienced OEM/ODM manufacturer, Kongdy Health understands the intricacies of UKCA marking and MHRA registration. We have a dedicated regulatory affairs team that stays abreast of the latest UK MDR developments and can guide you through every step of the compliance process. Whether you need assistance with technical documentation, UK Responsible Person services, or conformity assessment, we have the expertise to help.

Our state-of-the-art manufacturing facilities are certified to ISO 13485 and GMP, ensuring that your patches are produced to the highest quality standards. We also hold FDA registration, which demonstrates our commitment to regulatory excellence. By partnering with Kongdy Health, you can leverage our experience with UK regulatory submissions to accelerate your market entry and reduce compliance risks.

In addition, we offer end-to-end OEM services, from formulation development to packaging and labeling. Our team can ensure that your labels include the UKCA mark and all required information, such as the UK Responsible Person’s details. We also provide ongoing post-market surveillance support to help you meet MHRA reporting requirements. To learn more about how we can support your UKCA compliance, visit our OEM/ODM services page.

Frequently Asked Questions

Q1: What is the deadline for UKCA marking on transdermal patches?

The deadline for UKCA marking on most medical devices, including transdermal patches, was 1 July 2023. However, the UK government has granted extensions for certain low-risk devices (Class I) until 30 June 2028, provided they meet specific criteria. For Class IIa and IIb patches, the deadline has passed, and brands must comply immediately to continue selling in Great Britain. It’s crucial to check the MHRA website for the latest updates, as timelines may change.

Q2: Can I use CE marking instead of UKCA marking for patches sold in the UK?

No, CE marking is no longer accepted for medical devices placed on the market in Great Britain. Since 1 July 2023, UKCA marking is mandatory for most devices. However, for devices sold in Northern Ireland, CE marking or UKNI marking is still accepted. If you sell in both GB and Northern Ireland, you may need to apply both markings or use a dual-marking approach. It’s important to ensure that the correct marking is used for each market to avoid non-compliance.

Q3: What are the costs associated with UKCA marking for patches?

The costs for UKCA marking include MHRA registration fees, UK Approved Body fees, and costs for updating technical documentation and labeling. MHRA registration fees range from £100 for Class I devices to £2,000 for Class IIb devices. UK Approved Body fees for conformity assessment can range from £5,000 to £20,000 depending on the device’s complexity. Additionally, you may incur costs for appointing a UK Responsible Person, which can be around £2,000 to £5,000 annually. Overall, budgeting for UKCA compliance is essential, and partnering with an experienced OEM can help optimize costs.

Sources

• UK Government: Using the UKCA Marking
• MHRA: Medical Device Registration
• Grand View Research: Transdermal Patch Market Size Report, 2022
• ISO 13485: Medical Devices Quality Management